Regulatory T (Treg) cells represent key cellular players in the immune response, tasked with maintaining balance in immunity. Endowed with potent suppressive function, Treg cells maintain immune homeostasis, prevent autoimmunity, and curtail robust immune responses to prevent collateral tissue damage. These cells are critically important, and their insufficiency or loss results in autoimmunity. However, they can also be over- activated, preventing effective immunity to chronic viral infections and cancer. We and others hypothesize that Treg cells differ from conventional T cells not only in their function, but also in how they fuel that function. The intersection of metabolism and immunity has been of immense recent interest; our laboratory studies how energetics impacts immune cell function with a focus on immunity in the tumor microenvironment. We hypothesize that, as regulatory T cells exist out-of-sync with their conventional counterparts, suppressing autoimmunity or curtailing productive immunity in the tissues, they exhibit metabolic plasticity, able to persist and thrive on alternative metabolic substrates in the environment. Our preliminary studies support this hypothesis, using cancer as a model. Tumor-infiltrating Treg cells are extraordinarily active and proliferative, and maintain their epigenetic and lineage stability despite substantial inflammatory insults and thus represent a model of an exemplary regulatory cell. We have found that Treg cells `stratify' into distinct metabolic subsets with different suppressive capacities. This New Innovator project seeks to understand how the microenvironment, in cancer and in other diseases, promotes Treg cell function through metabolic symbiosis. We present evidence of alternative metabolic pathways utilizing byproducts of tumor cell metabolism that may support Treg cell function in the tissues. We will explore, based on transcriptomic profiles of these cells, which metabolites present in the tumor microenvironment support Treg cell function and epigenetic stability. Further, we have developed a novel system by which certain metabolic pathways can be enforced in a Treg cell-specific manner. Taken together, these studies will shed light on how these crucial cells are exploited by cancer to evade the immune response but also open up potential avenues by which these cells may be therapeutically modulated through metabolic means to prevent autoimmunity or promote the anti-tumor response in cancer.

Public Health Relevance

The immune system thrives on balance, weighting cells that can destroy infected or cancerous tissue with those that prevent attacking healthy tissue. However, this balance can be upset, resulting in autoimmune diseases or cancer. Regulatory T cells, which suppress immune responses, are lymphocytes which maintain this balance, but can be deregulated in many diseases: they are inefficient in autoimmune disease and hyperactive in cancer. This project seeks to understand how regulatory T cells thrive in certain environments, like cancer, by studying their metabolism: how they generate the energy they need for function. Cancer represents an environment which is depleted of fuel for infiltrating cells. Thus, it is surprising that regulatory T cells are so active there. We hypothesize that regulatory T cells have different metabolic requirements than other types of T cells, and that these energy sources underlie their very nature. We will use metabolic analysis and high-throughput sequencing to identify key differences in regulatory T cell metabolism in cancer. We believe that these studies will not only help us understand how to turn down the activity of these cells to promote anti-cancer immunity, but also how to activate these cells for the treatment of autoimmune disease.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
NIH Director’s New Innovator Awards (DP2)
Project #
1DP2AI136598-01
Application #
9348845
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Ramachandra, Lakshmi
Project Start
2017-09-01
Project End
2022-06-30
Budget Start
2017-09-01
Budget End
2022-06-30
Support Year
1
Fiscal Year
2017
Total Cost
Indirect Cost
Name
University of Pittsburgh
Department
Microbiology/Immun/Virology
Type
Schools of Medicine
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Rivadeneira, Dayana B; Delgoffe, Greg M (2018) Antitumor T-cell Reconditioning: Improving Metabolic Fitness for Optimal Cancer Immunotherapy. Clin Cancer Res 24:2473-2481
Revu, Shankar; Wu, Jing; Henkel, Matthew et al. (2018) IL-23 and IL-1? Drive Human Th17 Cell Differentiation and Metabolic Reprogramming in Absence of CD28 Costimulation. Cell Rep 22:2642-2653
Tilstra, Jeremy S; Avery, Lyndsay; Menk, Ashley V et al. (2018) Kidney-infiltrating T cells in murine lupus nephritis are metabolically and functionally exhausted. J Clin Invest 128:4884-4897
Vendetti, Frank P; Karukonda, Pooja; Clump, David A et al. (2018) ATR kinase inhibitor AZD6738 potentiates CD8+ T cell-dependent antitumor activity following radiation. J Clin Invest 128:3926-3940
Menk, Ashley V; Scharping, Nicole E; Moreci, Rebecca S et al. (2018) Early TCR Signaling Induces Rapid Aerobic Glycolysis Enabling Distinct Acute T Cell Effector Functions. Cell Rep 22:1509-1521
Menk, Ashley V; Scharping, Nicole E; Rivadeneira, Dayana B et al. (2018) 4-1BB costimulation induces T cell mitochondrial function and biogenesis enabling cancer immunotherapeutic responses. J Exp Med 215:1091-1100